A Phase 3 interventional study of Dexamethasone and Daratumumab in Multiple Myeloma, sponsored by Celgene. Active, not recruiting at 259 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing iberdomide in Multiple Myeloma — 11 open to participants now, 24 under way, 3 of them phase 3. iberdomide · Multiple Myeloma.
Among the 27 studies testing iberdomide in Multiple Myeloma, this one is the 2nd largest by enrollment, is one of 7 that started in 2022, is one of 3 in phase 3, reaches primary completion later than 10 of the 23 other live ones, and was the 4th registered.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →11 of the 27 studies testing iberdomide in Multiple Myeloma are open now, in 8 countries. Recruiting first, the newest first:
Alfred Chung, MD · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Canadian Myeloma Research Group · Sites in Canada
Ages 65+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Omar Nadeem, MD · Sites in United States
Ages 18+
By country, each count listing its studies:
iberdomide: first FDA approval 2026 (ZENBEXUS). What it is approved for, and how studies give it, is on its page →
Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 18 · Phase 3 3
First in 2016; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 939 is above the median of 41 across 3,009 interventional studies indexed under Multiple Myeloma.
Median enrollment 75 across the 27 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
5 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
149 studies in Multiple Myeloma by Bristol-Myers Squibb: 9 open now, 18 under way, 6 of them phase 3. Of 120 finished, 43 (36%) have results posted.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 4th largest by enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2022, is one of 30 in phase 3, reaches primary completion later than 10 of the 17 other live ones, and was the 128th registered.
Bristol-Myers Squibb’s Multiple Myeloma studies by the year they started, since 2001.
8 of the studies testing iberdomide in Multiple Myeloma that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05558319Phase 3PETHEMA FoundationNDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide | 2027-04 |
| NCT04975997Phase 3CelgeneOpen-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-11-16 |
| NCT05560399Icahn School of Medicine at Mount SinaiA Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | 2026-11 |
| NCT06465316National Cancer Institute (NCI)Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
| NCT05354557Memorial Sloan Kettering Cancer CenterStudy of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) | 2027-04-26 |
Add all 8 to your calendar (.ics) → With an account.
Among the 27 studies testing iberdomide in Multiple Myeloma, from their registry updates:
Among Bristol-Myers Squibb’s 149 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM). Approximately 200 patients randomized in stage 1 to one of three iberdomide dose levels of 1, 1.3, or 1.6 mg in combination with daratumumab and dexamethasone (Treatment Arms A1, A2, or A3), or to the DVd comparator arm (Treatment Arm B).
In Stage 2 of the study, approximately 664 additional subjects will be randomized 1:1 between 2 treatment arms:
Participants in both treatment arms will continue to receive treatment until confirmed progressive disease (PD), unacceptable toxicity or withdrawal of consent. To ensure accuracy and completeness of the primary endpoint assessment of progression-free survival (PFS), participants who permanently discontinue study treatment for any reason, other than confirmed PD or withdrawal of consent, will continue to be followed for disease assessment.
The study will be conducted in compliance with International Council for Harmonisation (ICH) and Good Clinical Practices (GCPs).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive oral iberdomide, subcutaneous daratumumab and oral dexamethasone.
Drug: Dexamethasone · Drug: Daratumumab · Drug: Iberdomide
Drug: Dexamethasone · Drug: Daratumumab · Drug: Iberdomide
Drug: Dexamethasone · Drug: Daratumumab · Drug: Iberdomide
Participants will receive subcutaneous daratumumab, bortezomib and oral dexamethasone
Drug: Dexamethasone · Drug: Bortezomib · Drug: Daratumumab
Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle
Also known as: DARZALEX FASPRO
Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.
Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle
Also known as: CC-220, BMS-986382
Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle
Also known as: CC-220, BMS-986382
Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle
Also known as: CC-220, BMS-986382
Oral dexamethasone 20mg on days 1,2, 4,5,8,9,11,12 of a 21-day cycle from cycles 1-8
Subcutaneous daratumumab 1800mg Cycles 1 to 3 on Days 1, 8, 15 of a 21-day cycle, Cycles 4 to 8 on Day 1 of a 21-day cycle and Cycles 9+ on Day 1 of a 28-day cycle.
Also known as: DARZALEX FASPRO
Progression-free Survival (PFS)
To compare the efficacy of iberdomide (also known as BMS-986382), daratumumab, and dexamethasone (IberDd) to that of daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM) in terms of progression free survival (PFS).
Time frame: Up to approximately 5 years
Minimal Residual Disease (MRD) negative Complete Response (CR) at any time
To compare the efficacy of iberdomide (also known as BMS-986382), daratumumab, and dexamethasone (IberDd) to that of daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM) in terms of minimal residual disease (MRD) negative complete response (CR) at any time.
Time frame: Up to approximately 5 years
Overall Survival (OS)
To evaluate clinical efficacy in terms of overall survival (OS) in participants with relapsed or refractory multiple myeloma (RRMM) treated with iberdomide, daratumumab, and dexamethasone (IberDd) compared to daratumumab, bortezomib, and dexamethasone (DVd).
Time frame: Up to approximately 5 years
Sustainability of Minimal Residual Disease (MRD) negativity
To evaluate the sustainability of minimal residual disease (MRD) negativity.
Time frame: Up to approximately 5 years
Overall Response Rate (ORR)
Calculated as percentage of participants who achieve best response of partial response (PR) or better according to the IMWG Uniform Response Criteria for multiple myeloma.
Time frame: Up to approximately 5 years
Time to response (TTR)
Time from randomization to the first documentation of response (PR or better).
Time frame: Up to approximately 5 years
Duration of Response (DoR)
Time from the first documentation of response (PR or better) to the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first.
Time frame: Up to approximately 5 years
Time to Progression (TTP)
The time from randomization to the first documented disease progression.
Time frame: Up to approximately 5 years
Time to Next Treatment (TTNT)
Time from randomization to the start of the next antimyeloma treatment.
Time frame: Up to approximately 5 years
Progression-free Survival 2 (PFS2)
Time from randomization to progression on the next anti-myeloma treatment or death due to any cause, whichever occurs first.
Time frame: Up to approximately 5 years
Safety
Type, frequency, seriousness and severity of adverse events (AEs), and relationship of AEs to study treatment.
Time frame: Up to approximately 5 years
European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30)
Mean changes from baseline in subscale scores in subject-reported health related quality of life outcomes and multiple myeloma-related symptoms as measured by the EORTC QLQ-C30.
Time frame: Up to approximately 5 years
European Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20)
EORTC QLQ-MY20 is a 20-item myeloma module intended for use among participants varying in disease stage and treatment modality. Mean changes from baseline in subscale scores in subject-reported health related quality of life outcomes and multiple myeloma-related symptoms as measured by the EORTC QLQ- MY20.
Time frame: Up to approximately 5 years
Recommended iberdomide dose for Stage 2
Time frame: Up to approximately 1 year
Area under the plasma concentration-time curve from time zero to tau (AUC(TAU))
Time frame: Up to approximately 1 year
Maximum plasma concentration (Cmax)
Time frame: Up to approximately 1 year
Time to maximum plasma concentration (Tmax)
Time frame: Up to approximately 1 year
Showing the first 100 of 259 sites across 31 countries. Choose a country and city above to see the rest.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Jun 2022 (actual). Primary completion is estimated for Nov 2027, 64 months after the start.
Of 109 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 64 months is above that.
Counting every sponsor, half of 181 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iberdomide